Skip to content
OpenCapital
Get started

Supernus Pharmaceuticals SUPN Accrued manufacturing expenses

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.58B+62.8%
Enterprise value$2.44B+62.3%
P/S3.3×+0.9×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept supn:AccruedManufacturingExpenses.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's accrued manufacturing expenses.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's accrued manufacturing expenses?
Supernus Pharmaceuticals (SUPN) reported accrued manufacturing expenses of $20.69M in Q1 2026.
How has Supernus Pharmaceuticals's accrued manufacturing expenses changed year-over-year?
Supernus Pharmaceuticals's accrued manufacturing expenses increased by 86.9% year-over-year, from $11.07M to $20.69M.
What is the long-term trend for Supernus Pharmaceuticals's accrued manufacturing expenses?
Over 3 years (2022 to 2025), Supernus Pharmaceuticals's accrued manufacturing expenses has grown at a 18.9% compound annual growth rate (CAGR), from $15.22M to $25.61M.